Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18 to $20.
Read original at benzingaFilings · News reference
Carlsmed Files Prospectus To Offer Up To $250M In Securities
-SEC Filing
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 8:31 PM
- Checked
- Aug 14, 2026, 8:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Carlsmed Raises FY2026 Sales Guidance from $72.000M-$77.000M to $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $72.000 million-$77.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
Read original at benzingaCarlsmed Q2 EPS $(0.39) Beats $(0.41) Estimate, Sales $18.940M Beat $17.948M Estimate
Read original at benzinga